1. Translating Data From Trial to Practice

3. Diabetes and the Cardiovascular Risk Spectrum

4. THEMIS Study Design

5. Moving Down the Spectrum of Vascular Risk

6. THEMIS History of Disease at Baseline

7. THEMIS Primary Results

8. THEMIS: Efficacy Endpoints Over 3 Years (ITT Population)

9. THEMIS: Prespecified Hierarchical Outcomes Over 3 Years (mITT Population)

10. THEMIS Efficacy Analysis: Prespecified Subgroups

11. Primary Efficacy Endpoint: Time Since PCI THEMIS-PCI Post Hoc Analysis

12. THEMIS: Safety Outcomes

13. THEMIS-PCI: Prespecified Subgroup Analysis

14. THEMIS-PCI: Prespecified Subgroup Analysis (cont)

15. THEMIS-PCI: Safety Outcomes

16. THEMIS: Events Prevented or Caused for 1000 Patients Treated With Ticagrelor + Aspirin

17. Identifying High-Risk Patients…

18. MI Is a Main Risk Driver SWEDEHEART Study

19. Similarities Between PEGASUS and THEMIS: Treatment Discontinuations

20. RCT vs On-Treatment Analysis

21. THEMIS-PCI On-Treatment Analysis Results

22. Whom Do You Treat?

23. How to Treat Non-PCI Patients

24. Applying CHARISMA to THEMIS-like Patients

25. Applying COMPASS to THEMIS-like Patients

26. Conclusions

27. Abbreviations

28. Abbreviations (cont)